Rapid Desensitization in Immediate Hypersensitivity Reaction to Drugs

被引：4

作者：

Giavina-Bianchi P. ^{[1
]}

Aun M.V. ^{[3
]}

Galvão V.R. ^{[1
]}

Castells M. ^{[1
]}

机构：

[1] Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

[2] Clinical Immunology and Allergy Division, University of São Paulo, R. Prof. Artur Ramos 178 ap.211A, Jd. América, São Paulo, CEP:01454-904, SP

来源：

Current Treatment Options in Allergy | 2015年 / 2卷 / 3期

关键词：

Adverse drug reaction; Anaphylaxis; Aspirin; Drug hypersensitivity reaction; Monoclonal antibodies; Platinum compounds; Protocol; Rapid drug desensitization; Taxanes; β-lactam antibiotics;

D O I：

10.1007/s40521-015-0060-2

中图分类号：

学科分类号：

摘要：

Adverse drug reactions have increased dramatically worldwide, often preventing the use of first-line therapies. Not infrequently, many patients presenting with drug hypersensitivity reactions are irreversibly labeled as allergic, fact that prevents them to receive the most appropriate treatment for their illnesses. Rapid drug desensitization has become a cornerstone in the management of immediate drug hypersensitivity reactions. It is the only effective procedure for overcoming hypersensitivity reactions to first-line therapy, thus representing an important advance in patients’ treatment and prognosis. Continued reports on the safety and efficacy of rapid drug desensitization emerging from different institutions are essential to allow the dissemination of desensitization programs. © 2015, Springer International Publishing AG.

引用

页码：268 / 285

页数：17

共 68 条

[21]

Gadducci A., Tana R., Teti G., Zanca G., Fanucchi A., Genazzani A.R., Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer, Int J Gynecol Cancer, 18, pp. 615-620, (2008)

[22]

Thomas R.R., Quinn M.G., Schuler B., Grem J.L., Hypersensitivity and idiosyncratic reactions to oxaliplatin, Cancer, 97, pp. 2301-2307, (2003)

[23]

Maindrault-Goebel F., Andre T., Tournigand C., Louvet C., Perez-Staub N., Zeghib N., Et al., Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients, Eur J Cancer, 41, pp. 2262-2267, (2005)

[24]

Caiado J., Venemalm L., Pereira-Santos M.C., Costa L., Barbosa M.P., Castells M., Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy, J Allergy Clin Immunol Pract, 1, pp. 494-500, (2013)

[25]

Polyzos A., Tsavaris N., Kosmas C., Arnaouti T., Kalahanis N., Tsigris C., Et al., Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience, Oncology, 61, pp. 129-133, (2001)

[26]

Dizon D.S., Sabbatini P.J., Aghajanian C., Hensley M.L., Spriggs D.R., Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy, Gynecol Oncol, 84, pp. 378-382, (2002)

[27]

Weiszhar Z., Czucz J., Revesz C., Rosivall L., Szebeni J., Rozsnyay Z., Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20, Eur J Pharm Sci, 45, pp. 492-498, (2012)

[28]

Prieto-Garcia A., de la Pineda Losa F., Immunoglobulin E-mediated severe anaphylaxis to paclitaxel, J Investig Allergol Clin Immunol, 20, pp. 170-171, (2010)

[29]

Picard M., Pur L., Caiado J., Giavina-Bianchi P., Galvao V., Castells M.C., Added value of skin testing in hypersensitivity reactions to taxanes, J Allergy Clin Immunol, 133, (2014)

[30]

Kwon J.S., Elit L., Finn M., Hirte H., Mazurka J., Moens F., Et al., A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel, Gynecol Oncol, 84, pp. 420-425, (2002)

← 1 2 3 4 5 6 7 →